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Background The human immunodeficiency virus (HIV) infectiousness of anal
intercourse (AI) has not been systematically reviewed, despite its
role driving HIV epidemics among men who have sex with men
(MSM) and its potential contribution to heterosexual spread. We
assessed the per-act and per-partner HIV transmission risk from AI
exposure for heterosexuals and MSM and its implications for HIV
prevention.
Methods Systematic review and meta-analysis of the literature on HIV-1
infectiousness through AI was conducted. PubMed was searched
to September 2008. A binomial model explored the individual risk
of HIV infection with and without highly active antiretroviral ther-
apy (HAART).
Results A total of 62 643 titles were searched; four publications reporting
per-act and 12 reporting per-partner transmission estimates were
included. Overall, random effects model summary estimates were
1.4% [95% confidence interval (CI) 0.2–2.5)] and 40.4% (95% CI
6.0–74.9) for per-act and per-partner unprotected receptive AI
(URAI), respectively. There was no significant difference between
per-act risks of URAI for heterosexuals and MSM. Per-partner un-
protected insertive AI (UIAI) and combined URAI–UIAI risk were
21.7% (95% CI 0.2–43.3) and 39.9% (95% CI 22.5–57.4), respective-
ly, with no available per-act estimates. Per-partner combined URAI–
UIAI summary estimates, which adjusted for additional exposures
other than AI with a ‘main’ partner [7.9% (95% CI 1.2–14.5)],
were lower than crude (unadjusted) estimates [48.1% (95% CI
35.3–60.8)]. Our modelling demonstrated that it would require un-
reasonably low numbers of AI HIV exposures per partnership to
reconcile the summary per-act and per-partner estimates, suggest-
ing considerable variability in AI infectiousness between and within
partnerships over time. AI may substantially increase HIV transmis-
sion risk even if the infected partner is receiving HAART; however,
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predictions are highly sensitive to infectiousness assumptions based
on viral load.
Conclusions Unprotected AI is a high-risk practice for HIV transmission, prob-
ably with substantial variation in infectiousness. The significant
heterogeneity between infectiousness estimates means that pooled
AI HIV transmission probabilities should be used with caution.
Recent reported rises in AI among heterosexuals suggest a greater
understanding of the role AI plays in heterosexual sex lives may be
increasingly important for HIV prevention.
Keywords HIV, anal intercourse, infectivity, transmission probability, review,
meta-analysis, HAART
Introduction
Studies systematically reviewing much-needed esti-
mates of human immunodeficiency virus (HIV)
infectiousness for various modes of transmission
have recently been published,1–4 partly in response
to discussions regarding the relative importance of
each mode for HIV epidemics world wide.1,2
However, none has specifically focused on anal
intercourse (AI), despite its role driving HIV epi-
demics among men who has sex with men
(MSM). AI may also contribute substantially to het-
erosexual epidemics in sub-Saharan Africa and
elsewhere.3
AI within heterosexual relationships is not an un-
common practice but is often underreported.4,5 It
is estimated that the absolute number of women
in the USA practising unprotected receptive AI
(URAI) is 7-fold higher than the number of MSM
practising URAI,6 while 75% of study participants in
the South African site of a multi-centre microbicides
trial reported URAI during follow-up.7
Highly active antiretroviral therapy (HAART) is
likely to substantially reduce risk from AI, as demon-
strated by randomized controlled trials for
mother-to-child transmission8 and observational stu-
dies for heterosexual partnerships.9,10 Although some
ecological evidence suggests a reduction in AI infec-
tiousness due to HAART may have occurred,11 no
direct empirical evidence is yet available. However,
the high infectiousness associated with AI, as
reviewed here, indicates that even with a substantial
reduction due to HAART, the residual infectiousness
could still present a high risk to partners, especially if
coupled with risk compensation.11
Our aims were systematically to review the literature
on estimates of unprotected AI (UAI) per-act and
per-partner transmission probabilities for heterosex-
uals and MSM, to investigate the relationship be-
tween per-act and per-partner summary estimates
and to explore the implications of practising URAI
for prevention of HIV transmission in the presence
of HAART.
Methods
The systematic review was undertaken following
MOOSE guidelines for reviews of observational
studies.12
Search strategy
As previously reported13 (details provided in
Supplementary data available at IJE online).
Selection criteria and data extraction
Empirical per-act and per-partner (irrespective of
partnership duration and frequency of sex acts) esti-
mates were extracted. Abstracts of pre-1990, studies
using sample sizes of less than 10 and estimates
derived from dynamic modelling studies fitted to em-
pirical HIV prevalence curves were excluded.
Estimates where infection of partners was ascertained
clinically14 or only through questioning the index,15
rather than by laboratory HIV diagnosis were
excluded. Per-partner estimates from studies of het-
erosexuals were restricted to including only those
sexual partners where AI was practised for 550% of
all sex acts within the partnership. There was no
other restriction by study design or language of pub-
lication. Each relevant publication was examined by
two investigators for data extraction.
Quantitative data synthesis and statistical
methods
Meta-analysis
Stata 10.0 produced random effects model summary
estimates. For studies not providing a point estimate,
the arithmetic midpoint of the confidence bounds or
estimate range was used. For studies reporting esti-
mates with an uncertainty range (reflecting uncer-
tainty to model assumptions) rather than a 95%
confidence interval (95% CI), a standard error or suf-
ficient information to derive these directly, we
approximated the standard error from symmetric
and asymmetric intervals as 1/1.96 the largest abso-
lute value (to account for asymmetric intervals) of the
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widths between the point estimate and the sensitivity
bounds.
Relationship between per-act and per-partner
transmission probability
We investigated the relationship between per-act and
per-partner AI transmission probabilities over n sex
acts using the following Bernouilli process that as-
sumes independence of risk for each sex act within
a partnership16,17:
p,a ¼ 1  1  c,að Þn ð1Þ
where p,a and c,a are the per-partner (p) and per-act
(c) transmission probability for AI (a), respectively.
For heterosexual populations practising both vaginal
intercourse (VI) and AI, Equation (1) becomes:
p,all ¼ 1  1  c,vð Þð1dÞn 1  c,að Þdn ð2Þ
where p,all is risk per-partner for VI and AI; c,v and
c,a are per-act transmission probabilities for VI (v)
and receptive AI (a), respectively; and d is the propor-
tion of n sex acts which are AI rather than VI.
Intervention impact: HAART
We assessed the potential reduction in HIV infectivity
caused by HAART reducing viral load, using two pub-
lished17–21 functions of infectivity by viral load. In
brief, the difference between the two functions is
that Function 1 was based on results from the
Rakai study of HIV transmission in heterosexual cou-
ples (presumed through VI transmission)22 and as-
sumes a linear relationship between infectiousness
and log serum viral load; Function 2 was based on
data from a Zambian cohort of discordant couples23
and assumed a logistic function between infectivity
and plasma viral load, which provides better fits to
the low number of transmissions observed for low
viral loads of index individuals.21 We assume that
successful HAART reduces blood viral load from an
average, baseline V0 to V1 copies/ml. Further details
are provided in the Supplementary data available at
IJE online.
Results
Search results
A total of 62 643 titles were searched and 27 poten-
tially appropriate publications were identified, three of
which were identified through bibliographies of
searched articles. Four publications reporting
per-act24–27 and 12 reporting per-partner28–39 esti-
mates were included. These were from MSM
(n¼ 1224,25,28,30–37,39), heterosexual (n¼ 326,27,29) or
mixed (n¼ 134) study populations. Per-partner esti-
mates from Nicolosi et al.’s study29 of heterosexuals,
where AI was practised ‘often or always’ (550% of all
intercourse) within the partnership were included;
those with less frequent practise were excluded.
Supplementary Figure S1 (available as
Supplementary data at IJE online) summarizes the
search strategy. All identified studies were from
industrialized countries. Figure 1 summarizes study
estimates for per-act and per-partner AI transmission
probabilities as forest plots, including summary esti-
mates from the meta-analyses. Details of included
and excluded studies are in Supplementary Tables
S1 and S2 (available as Supplementary data at IJE
online), respectively. Supplementary Table S3 (avail-
able as Supplementary data at IJE online) summar-
izes heterosexual per-partner estimates that have been
stratified by frequency of AI practice. Supplementary
Table S4 (available as Supplementary data at IJE
online) summarizes AI study estimates stratified by
different risk factors.
The only per-act estimates included were for URAI.
Vittinghoff et al.’s25 estimates for protected receptive
AI (0.18%, 95% CI 0.10–0.28), unprotected insertive
AI (UIAI) (0.06%, 95% CI 0.02–0.19) and protected
insertive AI (0.04%, 95% CI 0.01–0.11), based on part-
ners of index cases who were ‘‘HIV infected or of
unknown serostatus’’, were excluded because no at-
tempt was made to estimate the unknown HIV status
of index cases by using HIV prevalence as a proxy for
exposure to an HIV-infected partner.
Study design and estimate type
The included studies employed three study designs:
retrospective-partner (n¼ 1124,26–34,37), prospective
discordant-couple (n¼ 136) and simple-prospective
(longitudinal cohort, n¼ 425,35,38,39) studies. In
retrospective-partner studies, the infection status of
each partner becomes known only at the time of the
study. The index case and time of infection are deter-
mined based on exposure to a salient risk factor. In
prospective discordant-couple studies, stable (prefer-
ably monogamous) HIV-serodiscordant couples are
followed up after diagnosis of the index partner.
These studies also provide per-partner HIV transmis-
sion rates but, with only one included study (and only
10 couples36), we report and use cross-sectional
results at the end of follow-up for the meta-analysis.
With simple-prospective studies, individuals (not
necessarily monogamous) are recruited following
sexual contact with potentially infected, high-risk
partners and serostatus monitored. As index cases
are not recruited, HIV exposure is estimated using
HIV prevalence in the pool of potential partners and
the reported coital frequency. Therefore, prospective
studies suffer from problems of selection bias
(prospective discordant-couple) and uncertainty in
estimating the numbers of HIV exposures
(simple-prospective) and are not necessarily superior
to the retrospective-partner study design.
Per-act estimates were derived from retrospective-
partner (n¼ 324,26,27) and simple-prospective
(n¼ 125) studies. Per-partner estimates were derived
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from retrospective-partner (n¼ 828–34,37), prospective-
discordant couple (n¼ 136) and simple-prospective
(n¼ 335,38,39) studies. For both URAI-only and
UIAI-only per-partner estimates, three were derived
from retrospective-partner29,31,34 and one from
simple-prospective39 study data.
We categorized study estimates into ‘crude’ and ‘ad-
justed’. ‘Crude’ estimates are based on the HIV status
of partners of index cases and assume that the index
case was the only source of exposure. In high-risk
populations, multiple exposures to HIV through
sexual contact with other partners and through
other types of sexual practice may lead to overesti-
mation of infectivity. Thus, ‘adjusted’ estimates are
based on statistical models to control for multiple ex-
posures. One study also adjusted for multiple modes
of sexual transmission: URAI, UIAI, protected AI and
oro-genital intercourse.25 No study provided both
crude and adjusted estimates. Brief details on ad-
justed estimates are provided in Supplementary
Table S1 (available as Supplementary data at IJE
online). Numbers of per-act and per-partner estimate
by adjustment type and study design are given in
Table 1. For per-partner transmission probabilities,
retrospective-partner studies reported crude estimates,
whereas prospective studies tended to report adjusted
estimates, which made it difficult to disentangle the
effect of study design from adjustment for multiple
exposures. In addition, all estimates where the stand-
ard error had to be approximated using an uncer-
tainty range quoted by authors were adjusted
estimates.
(a)
(b)
Figure 1 Forest plot of studies estimating HIV transmission probabilities for AI expressing risk as (a) per-act and
(b) per-partner. For crude estimates (unfilled boxes), the size of box represents relative study sample size. Adjusted
estimate (filled Rhombus), Crude estimate based on x number of seroconverting partners among n couples with an infected
index partner (open square), Summary estimate (filled squre)
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Infectiousness of AI for heterosexuals
and MSM
Table 1 shows the per-act and per-partner summary
estimates by exposure (combined URAI–UIAI,
URAI-only and UIAI-only). Two per-act URAI esti-
mates were based on studies among MSM24,25 and
two among heterosexual couples.26,27 The per-act
summary estimate was 1.4% (95% CI 0.2–2.5) (or
1.8% (95% CI 0.3–3.2) if Halperin et al.’s26 abstract
estimate is excluded due to lack of further detail on
methods). No significant differences in per-act URAI
estimates between heterosexual couples and MSM
were found (P¼ 0.674). However, while MSM esti-
mates24,25 were similar to each other (Q¼ 0.2;
P¼ 0.635; I2¼ 0%), heterosexual estimates26,27 were
heterogeneous (Q¼ 10.5; P¼ 0.001; I2¼ 90%;
Figure 1; Table 1). Most per-partner estimates were
derived from studies on MSM. Exceptions were the
studies by Nicolosi et al.29 studying heterosexual cou-
ples, and Giesecke et al.34 who enrolled a small pro-
portion of heterosexual participants. Cheingsong-
Popov et al.28 did not describe study participants but
it appears likely, given the 1984 publication date, that
the acquired immunodeficiency syndrome (AIDS) and
AIDS-related complex patients reporting AI were
MSM. There was no evidence that the heterosexual
combined URAI–UIAI crude per-partner estimate29
was significantly different from the eight crude esti-
mates from MSM (P¼ 0.821).
Reliability of estimates
All per-partner summary estimates displayed consid-
erable heterogeneity. Summary estimates calculated
using adjusted estimates were considerably lower
than those using crude estimates (Figure 1;
Table 1). However, the reliability of summary adjusted
estimates is questionable because only the crude
combined URAI–UIAI summary estimate was based
on more than five estimates. Interestingly, while
crude per-partner estimates from MSM populations
may overestimate per-partner infectivity because of
competing exposures due to frequent lack of monog-
amy,28,30–34,36,37,39 they were in good agreement with
crude per-partner estimates from heterosexual couples
reporting high frequency of AI and 100% monogamy29
(Figure 1).
For combined URAI–UIAI, the summary estimate
based on crude estimates only was 48.1% (95% CI
35.3–60.8), for URAI-only 51.4% (95% CI 28.1–74.7)
and for UIAI-only 29.4% (95% CI 16.0–42.9)
(Table 1). The forest plot (Figure 1) and Q- and
I2-statistics (Table 1) highlight significant residual
heterogeneity across estimates, even after excluding
adjusted estimates. Nicolosi et al.’s29 study partici-
pants reported 100% monogamy, yet the 42.9% (95%
CI 29.1–57.8) combined URAI–UIAI risk is more con-
sistent with the crude MSM study estimates despite
potential contamination from competing HIV expos-
ures, than the adjusted MSM estimates. Separating
combined URAI–UIAI estimates by study design (pro-
spective35,36,38 versus retrospective28–34,37) gave simi-
lar findings because both adjusted estimates were
derived from simple-prospective studies and the re-
maining prospective study, of serodiscordant couples,
was small (n¼1036).
Heterogeneity of infectiousness
Despite providing a single per-act URAI estimate,
DeGruttola et al.24 discussed variability of infectious-
ness between individuals and suggested that 10–20%
of infected MSM may have far greater infectiousness
(about 510% per-act). Supplementary Table S4
(available as Supplementary data at IJE online) sum-
marizes the few per-act and per-partner estimates
stratified by risk factors. The only per-act estimate
stratified by infection stage [primary infection and
AIDS stages each separately estimated as 18.35%
(95% CI 2.08–34.6); asymptomatic incubation stage
1.38% (95% CI 0.0–3.38)]27 reflects the variability in
infectiousness within an individual over time.
However, it is likely that none of the four average
per-act AI infectivity estimates adequately captures
the contribution of high infectiousness during acute,
pre-seroconversion infection.24–27 The study by
Leynaert et al.27 was a retrospective-partner study
where the exposure period was only crudely esti-
mated. Although some transmissions in Vittinghoff
et al.’s prospective study might have occurred as a
result of acute infection exposure, the study estimate
included only study participants reporting partners
known to be HIV infected. Therefore, the index
cases were unlikely to be in the highly infectious
acute HIV stage because of the time lag between in-
fection and HIV diagnosis and disclosure of their
status to their partners included in the study.
Therefore, the true average per-act infectivity across
all infection stages may be higher than our 1.4% sum-
mary estimate because retrospective-partner studies
may miss the acute infection stage, or may be lower
because Vittinghoff’s prospective study may have mis-
attributed some transmission events from unidenti-
fied HIV exposures.
Relationship between per-act and
per-partner infectivity for AI
Figure 2 illustrates the relationship between per-act
and cumulative HIV risk over a partnership through
URAI (by number of sexual acts), compared with
per-partner combined URAI–UIAI summary estimates
from our meta-analysis (drawn as horizontal lines).
The figure indicates, for example, that only 36 URAI
acts would be required to produce the per-partner
combined URAI–UIAI summary estimate of 39.9% if
we assume that per-act URAI HIV transmission prob-
ability is 1.4%. If 50% of acts are receptive and 50%
insertive, 60 UAI acts are required if we assume that
UIAI per-act risk is 0.3% (same as for VI; see Figure 2
legend for details) and 51 acts if the UIAI per-act risk
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is 0.6%. Competing risk from UIAI increases the total
number of unprotected acts necessary for transmis-
sion per partnership only by relatively modest
amounts, especially when the increase in transmission
probability of UIAI compared with VI is large, because
UIAI infectiousness becomes closer to that of URAI.
As suggested previously,24 under the model assump-
tions, it is difficult to explain per-partner risk esti-
mates as a function of per-act estimates. The results
imply relatively few UAI acts per relationship among
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Figure 2 Relation between per-partner HIV transmission risk (cumulative probability of HIV transmission) and the number
of sexual acts with an HIV infected partner, using our summary per-act URAI estimate of 1.4% (95% CI 0.2–2.5). The
intersection between the modelled per-partner HIV transmission risk (y-axis) and our meta-analytic per-partner combined
URAI–UIAI summary estimates (plotted as horizontal lines) predicts the required average number of acts per partnership (x-
axis), under our model assumptions (see ‘Methods’ section). Adjusted estimates control for exposures due to multiple
partners and crude estimates do not. (a) All acts assumed to be URAI; (b) 50% acts URAI, 50% acts UIAI, assuming that
per-act UIAI has the same HIV transmission probability as penile–vaginal intercourse (summary estimate of per-act penile–
vaginal intercourse, male-to-female transmission for developing countries: 0.3%13; (c) as for (b) but UIAI HIV transmission
probability is 0.6%. Competing risk from UIAI increases the total number of unprotected acts necessary for transmission per
partnership only by relatively modest amounts, especially when the increase in transmission probability of UIAI compared
with VI is large, because UIAI infectiousness becomes closer to that of URAI.
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the partnerships included in the per-partner studies.
As too few MSM per-partner studies reported length
of partnership or number of sex acts per partnership
(Supplementary Table S1, available as Supplementary
data at IJE online), it is difficult to test this hypoth-
esis. Although some of the partnerships in the
per-partner studies may have been relatively short
with few sexual acts, this is unlikely to be the case
for all partnerships and all studies. For example,
Nicolosi et al.29 reported a median partnership dur-
ation of 2.9 years, implying a relatively large number
of acts. Supplementary Figure S2 (available as
Supplementary data at IJE online) shows how empir-
ical per-partner study estimates do not show the ex-
pected increase in infectivity with increasing number
of sexual exposures to the index partner predicted by
the Bernoulli process [Equation (1)] in absence of
heterogeneity. The discrepancies between per-act and
per-partner estimates (Figure 2; Supplementary
Figure S2, available as Supplementary data at IJE
online) may partly be explained by condom use, com-
peting risks from exposure to HIV outside the main
partnership or some degree of heterogeneity in trans-
mission probability per-act between individuals and
within individuals over time, implying that our as-
sumption of independence of risk per-act within a
partnership is invalid. If there is heterogeneity in in-
fectiousness or susceptibility between individuals, this
may explain the saturation of per-partner risk at
lower levels than predicted using our per-act sum-
mary estimate. The four per-act estimates represent
exposure without condoms: DeGruttola et al.24 and
Leynaert et al.27 reported <1% condom use and
Vittinghoff et al.25 and Halperin et al.26 adjusted for
it. In contrast, many per-partner studies reported
‘some condom use’ but generally did not quantify fre-
quency (although it appears that condom use was
generally very inconsistent within partnerships).
If we assume the 18.35% per-act URAI estimate of
Leynaert et al.27 associated with primary infection,
only three URAI acts were necessary for per-partner
HIV risk to exceed 40.4% (per-partner URAI-only
summary estimate, results not shown). Therefore,
high infectiousness associated with primary infection
may account for the high per-partner estimates
observed for some partnerships consisting of few
acts. However, relatively few short duration partner-
ships are likely to occur while infected individuals
experience primary infection, because this period is
very short [3 months40], although this will depend
on the sexual network structure. Late-stage infection
is also associated with high infectiousness,27 so the
same argument could apply, although sexual activity
of AIDS patients is likely to be much lower.
Implications for the effectiveness of
interventions: HAART
Figure 3a illustrates the relationship between
per-partner HIV risk and total sex acts involving
exposure to HIV-infected partners not on HAART,
considering both VI/UIAI and URAI exposure (see
legend for details). Using Function 1 (Figure 3b),
the predicted HIV transmission probabilities per-act
for VI/UIAI and URAI with successful HAART are
0.013 and 0.061%, respectively, i.e. 96% lower than
without therapy. Under these assumptions, 1000 sex
acts leads to a male-to-female per-partner HIV risk of
12.2% if no AI is practised (i.e. only VI is practised)
and 12.6, 14.3, 16.3 and 20.2% if AI is practised for 1,
5, 10 and 20% of all sex acts, respectively. For MSM,
1000 acts lead to per-partner risk of 30.9% if partners
alternate URAI and UIAI, and 45.6% if the initially
uninfected partner is always receptive. As expected,
our per-partner HIV risk estimates with HAART,
even assuming continuous viral suppression, are
larger than Wilson et al.’s17 estimates using the
same function, because we used recent and higher
baseline per-act VI infectivity estimates from the stu-
dies of developing country only (due to the lack of AI
infectivity studies from developing countries, per-act
URAI was informed by the studies of developed coun-
try only).13 Using Function 2 (Figure 3c–e), the pre-
dicted per-act VI/UIAI and URAI estimates with
successful HAART are 0.0002 and 0.0011%, respective-
ly, i.e. 99.9% lower than without therapy. Under these
assumptions, 1000 sex acts lead to a male-to-female
per-partner HIV risk of <0.5% even where AI consti-
tutes 20% of all sex acts, <1% for MSM practising
URAI and UIAI with equal frequency and 1.1% for
MSM solely practising URAI (Figure 3c). However, if
viral rebound occurs due to treatment failure,
per-partner transmission risks become much larger
(Figure 3d–e).
Discussion
Four per-act URAI estimates produced a summary es-
timate of 1.4% (95% CI 0.2–2.5) and per-partner sum-
mary estimates were 39.9% (95% CI 22.5–57.4), 40.4%
(95% CI 6.0–74.9) and 21.7% (95% CI 0.2–43.3) for
combined URAI–UIAI, URAI and UIAI transmission,
respectively. Competing risk from UIAI only margin-
ally increases HIV transmission per partnership
(39.9% for combined, 40.4% for URAI-only), which
supports the hypothesis that UIAI is substantially
less infectious than URAI. However, the significant
heterogeneity between per-partner estimates led to
wide CIs, primarily due to differences in analytic
methods and study design. Thus, these ‘average’ AI
transmission probabilities should be used with
caution.
The large discrepancy between crude and adjusted
per-partner estimates (Table 1) makes interpretation
of the results particularly difficult, especially because
similar adjustments used to quantify per-act VI esti-
mates were found to have little impact.13,41 The com-
bined URAI–UIAI summary estimate using adjusted
per-partner estimates was approximately six times
HIV INFECTIOUSNESS OF ANAL INTERCOURSE 1055
0.
0%
0.
2%
0.
4%
0.
6%
0.
8%
1.
0%
0
20
0
40
0
60
0
80
0
10
00
N
um
be
r 
o
f u
n
pr
ot
ec
te
d 
se
xu
a
l a
ct
s
0%20
%
40
%
60
%
80
%
10
0%
0
20
0
40
0
60
0
80
0
10
00
per-partner HIV risk
N
um
be
r 
o
f u
n
pr
ot
ec
te
d 
se
xu
a
l a
ct
s
0%20
%
40
%
60
%
80
%
10
0%
0
20
0
40
0
60
0
80
0
10
00
per-partner HIV risk
N
um
be
r 
o
f u
n
pr
ot
ec
te
d 
se
xu
a
l a
ct
s
Fr
e
qu
en
cy
of
se
x
a
ct
s
in
vo
lvi
ng
re
ce
pt
ive
AI
0% 1% 5% 10
%
20
%
50
%
10
0%
0%20
%
40
%
60
%
80
%
10
0%
0
20
0
40
0
60
0
80
0
10
00
per-partner HIV risk
N
um
be
r 
o
f u
n
pr
ot
ec
te
d 
se
xu
a
l a
ct
s
Ti
m
e
w
ith
vir
a
lr
e
bo
un
d:
80
%
,r
e
bo
un
d
to
50
00
co
pi
es
/m
l
Ti
m
e
w
ith
vir
a
lr
e
bo
un
d:
20
%
,r
e
bo
un
d
to
50
00
co
pi
es
/m
l
Ti
m
e
w
ith
vir
a
lr
e
bo
un
d:
80
%
,r
e
bo
un
d
to
50
0
co
pi
es
/m
l
Ti
m
e
w
ith
vir
a
lr
e
bo
un
d:
20
%
,r
e
bo
un
d
to
50
0
co
pi
es
/m
l
0%20
%
40
%
60
%
80
%
10
0%
0
20
0
40
0
60
0
80
0
10
00
per-partner HIV risk
N
um
be
r 
o
f 
u
n
pr
ot
ec
te
d 
se
xu
a
l a
ct
s
(a)
(b
)
(c) (e)
(d
)
F
ig
u
re
3
R
el
a
ti
o
n
b
et
w
ee
n
p
er
-p
a
rt
n
er
H
IV
ri
sk
(c
u
m
u
la
ti
ve
p
ro
b
a
b
il
it
y
o
f
H
IV
tr
a
n
sm
is
si
o
n
)
a
n
d
th
e
n
u
m
b
er
o
f
a
ll
se
x
u
a
l
a
ct
s
(w
h
et
h
er
p
en
il
e–
va
g
in
a
l
o
r
p
en
il
e–
a
n
a
l)
th
a
t
u
n
in
fe
ct
ed
M
S
M
o
r
h
et
er
o
se
x
u
a
l
w
o
m
en
a
re
ex
p
o
se
d
to
w
it
h
H
IV
-i
n
fe
ct
ed
m
en
,
ex
p
lo
ri
n
g
th
e
im
p
a
ct
o
f
d
if
fe
re
n
t
fr
eq
u
en
ci
es
o
f
U
R
A
I
w
it
h
in
th
e
p
a
rt
n
er
sh
ip
(i
f
in
a
m
o
n
o
g
a
m
o
u
s
H
IV
d
is
co
rd
a
n
t
re
la
ti
o
n
sh
ip
)
o
r
a
m
o
n
g
a
ll
se
x
u
a
l
H
IV
ex
p
o
su
re
s
th
a
t
a
n
u
n
in
fe
ct
ed
in
d
iv
id
u
a
l
en
co
u
n
te
rs
.
F
re
q
u
en
cy
o
f
se
x
u
a
l
a
ct
s
in
vo
lv
in
g
U
R
A
I:
0
–
2
0
%
re
p
re
se
n
t
ra
n
g
es
fo
r
w
o
m
en
in
h
et
er
o
se
x
u
a
l
p
a
rt
n
er
sh
ip
s,
w
it
h
th
e
re
m
a
in
d
er
o
f
se
x
u
a
l
ex
p
o
su
re
s
a
ss
u
m
ed
to
b
e
p
en
il
e–
va
g
in
a
l;
5
0
%
re
p
re
se
n
ts
M
S
M
p
a
rt
n
er
sh
ip
s
w
h
er
e
ea
ch
p
a
rt
n
er
p
ra
ct
is
es
U
R
A
I
a
n
d
U
IA
I
eq
u
a
ll
y
o
ft
en
;
1
0
0
%
re
p
re
se
n
ts
M
S
M
w
h
er
e
th
e
se
ro
n
eg
a
ti
ve
p
a
rt
n
er
is
a
lw
a
ys
re
ce
p
ti
ve
.
S
ce
n
a
ri
o
(a
)
re
p
re
se
n
ts
th
e
im
p
a
ct
o
f
U
R
A
I
o
n
p
er
-p
a
rt
n
er
H
IV
ri
sk
a
ss
u
m
in
g
a
co
n
st
a
n
t
p
er
-a
ct
p
ro
b
a
b
il
it
y
fo
r
U
R
A
I
(1
.4
%
,
T
a
b
le
1
)
a
n
d
fo
r
p
en
il
e–
va
g
in
a
l
in
te
rc
o
u
rs
e
(s
u
m
m
a
ry
es
ti
m
a
te
o
f
p
er
-a
ct
p
en
il
e–
va
g
in
a
l
in
te
rc
o
u
rs
e,
m
a
le
-t
o
-f
em
a
le
tr
a
n
sm
is
si
o
n
fo
r
d
ev
el
o
p
in
g
co
u
n
tr
ie
s:
0
.3
%
1
3
;
w
e
a
ss
u
m
e,
in
th
e
a
b
se
n
ce
o
f
p
er
-a
ct
H
IV
es
ti
m
a
te
s
fo
r
U
IA
I
id
en
ti
fi
ed
b
y
o
u
r
re
vi
ew
,
th
a
t
H
IV
tr
a
n
sm
is
si
o
n
p
ro
b
a
b
il
it
y
is
th
e
sa
m
e
a
s
fo
r
fe
m
a
le
-t
o
-m
a
le
p
en
il
e–
va
g
in
a
l
in
te
rc
o
u
rs
e)
.
S
ce
n
a
ri
o
(b
)
u
se
s
F
u
n
ct
io
n
1
to
in
ve
st
ig
a
te
im
p
a
ct
o
f
H
A
A
R
T
,
p
re
d
ic
ti
n
g
p
er
-p
a
rt
n
er
H
IV
ri
sk
w
it
h
in
a
d
is
co
rd
a
n
t
co
u
p
le
w
h
er
e
th
e
in
d
ex
m
a
le
h
a
s
su
cc
es
sf
u
l
vi
ra
l
su
p
p
re
ss
io
n
d
u
e
to
H
A
A
R
T
.
S
ce
n
a
ri
o
(c
)
in
ve
st
ig
a
te
s
th
e
sa
m
e,
b
y
u
si
n
g
F
u
n
ct
io
n
2
(n
o
te
ch
a
n
g
e
o
f
y-
a
x
is
sc
a
le
).
S
ce
n
a
ri
o
s
(d
)
a
n
d
(e
)
u
se
F
u
n
ct
io
n
2
(s
ep
a
ra
ti
n
g
g
ra
p
h
s
fo
r
w
o
m
en
a
n
d
M
S
M
fo
r
cl
a
ri
ty
),
a
d
d
it
io
n
a
ll
y
in
cl
u
d
in
g
vi
ra
l
re
b
o
u
n
d
a
s
a
re
su
lt
o
f
tr
ea
tm
en
t
fa
il
u
re
fo
r
a
p
ro
p
o
rt
io
n
o
f
th
e
d
u
ra
ti
o
n
o
f
ex
p
o
su
re
.
T
h
e
d
er
iv
ed
re
la
ti
o
n
sh
ip
b
et
w
ee
n
U
R
A
I
in
fe
ct
io
u
sn
es
s
a
n
d
p
la
sm
a
vi
ra
l
lo
a
d
ca
lc
u
la
te
d
in
F
u
n
ct
io
n
2
is
il
lu
st
ra
te
d
in
S
u
p
p
le
m
en
ta
ry
F
ig
u
re
S
3
(a
va
il
a
b
le
a
s
S
u
p
p
le
m
en
ta
ry
d
a
ta
a
t
IJ
E
o
n
li
n
e)
.
1056 INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
lower than for the summary of crude estimates. As
many MSM study subjects may have multiple part-
ners, adjusted estimates may be more reliable.
However, the 42.9% (95% CI 29.1–57.8) crude
per-partner estimate reported by Nicolosi et al.29 for
heterosexual relationships with high levels of monog-
amy, together with the high per-act estimates identi-
fied, are difficult to reconcile with the low summary
estimate for adjusted per-partner infectiousness. Most
studies did not collect the necessary sexual activity
information required to gain a better understanding
of the relationship between per-act and per-partner
risk. Variation across study estimates may also
partly be explained by differences in distributions of
risk factors in sampled populations, study designs and
various (time-varying) characteristics of the type of
sexual behaviour, characteristics of the infected part-
ner and those of the uninfected partner. For example,
duration of exposure to an infected partner, frequency
of unprotected acts per-partner and presence of vari-
ous cofactors for transmission, such as condom use,
will differ (Supplementary Table S1, available as
Supplementary data at IJE online). While HIV trans-
mission for heterosexual men engaging in AI will pre-
dominantly occur by insertive intercourse, MSM
experience risk through both insertive and/or recep-
tive AI.
As suggested previously,24 the difficulty in reconcil-
ing per-act and per-partner estimates highlights the
difficulty in specifying a unique estimate of AI and
supports that there is considerable heterogeneity in
infectivity between individuals, over the course of in-
fection and/or that our assumption of independence
of risk per-act within a partnership is invalid.42
DeGruttola et al.24 suggested in 1989 that such het-
erogeneity leads to underestimation of the number of
partners who would be infected after few acts and
overestimation of numbers who would be infected
after many acts. Heterogeneity in per-act or
per-partner HIV infectiousness has also been reported
in other studies for VI13,41 and intercourse for
MSM.27,33,34 Additional evidence of heterogeneity in
per-partner estimates by potential risk factors such as
STI history are summarized in Supplementary Table
S4 (available as Supplementary data at IJE online),
but the number of studies is limited. Estimates stra-
tified by risk categories (Supplementary Tables S3 and
S4, available as Supplementary data at IJE online)
may suffer from publication bias, as they are more
likely to be reported if differences are significant.
URAI per-act estimates are substantially higher than
for male-to-female VI (0.08%, 95% CI 0.06–0.11 in
developed countries; 0.30%, 95% CI 0.14–0.63 in
developing countries).13 Most studies of heterosexual
couples have found an increased male-to-female
transmission risk among couples practising AI, even
if only occasionally.13,41,43–50 Rectal mucosa lacks the
protective humoral immune barrier present in cervi-
covaginal secretions51 and is more susceptible to
traumatic abrasions which may facilitate transmis-
sion.52 We found no evidence of a difference in
per-act AI infectivity between heterosexual and
MSM couples, possibly because they are biologically
similar practices, yet per-partner infectivities may
differ due to dissimilar frequencies of practising AI
within heterosexual and MSM relationships.
However, the only heterosexual per-partner study
consisted of couples with high frequency of AI
(550% of sexual acts)29 and therefore, given the
much higher risk of transmission during AI than VI,
estimates should be comparable with those from
MSM studies. Our review extends previous HIV in-
fectivity research because we investigated per-act
and per-partner AI infectivity among MSM and het-
erosexuals. However, we found no AI estimates from
developing countries, and given the different distribu-
tions in risk factors such as STI prevalences and HIV
subtypes between settings, we may underestimate
overall AI infectiousness for developing countries, as
has been suggested for per-act VI infectiousness.13,41
Our AI transmission probability estimates are con-
siderably higher than oro-genital risks, which were
found to be very low, but non-zero.53 For example,
our per-act URAI summary estimate is 35-fold larger
than the highest per-act oro-genital estimate
(0.04% for unprotected receptive oro-genital inter-
course, 95% CI 0.01–0.1725). Thus, practising oral
sex with an HIV-infected individual considerably re-
duces the risk of HIV acquisition compared with that
for URAI and UIAI, but does not reduce it to zero.
Individuals often make sophisticated choices regard-
ing the balance of risk and pleasure;54,55 this differ-
ence in risk should be appropriately communicated to
relevant populations.
Studies have demonstrated that a substantial per-
centage of heterosexuals engage in AI with an
opposite-gender partner56–60 and that rates of
condom use for heterosexual AI are lower than for
VI.6,61 More recently, research in the USA and the
UK has demonstrated an increase in the proportion
of heterosexuals reporting practicing AI,56,62–64 al-
though this rise may be attributable to social changes
affecting reporting bias. The proportion of heterosexu-
ally acquired HIV infection attributable to AI depends
largely on the frequency of UAI, which varies greatly
by population and setting, and the HIV risk profile of
the partners of heterosexuals. Table 2 presents a sum-
mary of studies identified through a non-exhaustive
review of PubMed, documenting the proportion of
participants reporting any AI over a defined
period for various populations and settings published
in the last 10 years. Although these findings may not
all be representative of the general population due to
small samples and selection biases, the high rates of
AI are in line with those investigated with our model.
The majority of surveys were conducted in industria-
lized countries; more and carefully collected data on
frequency of protected and unprotected AI are
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Table 2 Summary of selected epidemiological studies investigating practice of AI among heterosexual populations
published in the last 10 years
Study Population Age (years) Sample
size
AI reported
(%)
Exposure
period
Industrialized countries
Pollack, 1999,
unpublished data;
National AIDS
Behavioral
Methodology
Studya,b
USA population survey,
women
18–49 1071 6.10 Past 6 months
Laumann et al., 199474,a USA population survey 18–59 3432 23 Ever
10 men Past year
9 women Past year
2.3 men Last sex
1.2 women Last sex
50–54 3 men Past year
2 women Past year
25–29 2.4 women Last sex
Gross et al., 200060 USA HIV negative
women ‘at high risk of
HIV infection’
11% 18–25 1268 32 Past 6 months
38% 26–35
51% 536
Baldwin and Baldwin,
200057
USA random sample of
sexually experienced
university students
(oversampling ethnic
groups)
Mean 21, all
<30
647 23 Ever
Johnson et al., 200164 UK population-based
survey (NATSAL)
16–44 111 613c 7.0 men Past year (1990)
6.5 women
12.3 men Past year (2000)
11.3 women
Friedman et al., 200158 USA women, inner city
minority neighbourhood
18–24 202 14 Past year
Flannery et al., 200375 USA sexually experi-
enced female college
students 1993–2000
NR 761 32 Ever
Leichliter et al., 200761 USA general population
survey
15–44 12 571 30 women Ever
34 men
Houston et al., 200776 USA inner city adoles-
cent, sexually experi-
enced females
12–18 350 16 main
partners
Past 3 months
12 casual
partners
Tian et al., 200877 USA STD clinic
attendees
15–39 2357 18.30 Past 3 months
39.30 Past year
Developing countries
Karim and
Ramjee, 199878
South Africa FSW sur-
veyed at truck stops
Mean 24 145 43 with
clients
Ever
Matasha et al., 199879 Tanzania cohort of
sexually experienced
male and female school
pupils
Median 15,
12–20
661 6 First sexual
experienced
Sallah et al., 199980 Togo female college
students
20–29 817 9 Likely currentlye
37.80 Likely evere
Fonck et al., 200081 Kenya FSW cohort Mean 32 318 14 Likely evere
Ramjee and
Gouws, 200282
South Africa truck
drivers
Mean 37,
18–71
184 42 Likely evere
Ferguson and
Morris, 200383
Kenya FSW cohort NR 339 20 Ever
Lane et al., 200684 South Africa national
survey of adolescent
sexual behaviours, sexu-
ally active respondents
15–24 7976 5.3 women Ever
5.5 men
Schwandt et al., 200685 Kenya FSW cohort Mean 35,
15–63
147 40.80 Ever
Skoler-Karpoff
et al., 200870
South Africa, baseline
characteristics from a
microbicide RCT,
516 (4%
16–17, 33%
6202 2f Past 3 months
(continued)
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required from populations in developing countries
to explore the influence of AI on generalized
epidemics.65
Our analysis of how the impact of HAART on HIV
transmission may be mitigated by AI suffers from sev-
eral limitations due to its simplicity and the difficulty
in quantifying AI infectiousness highlighted in this
review (e.g. per-act VI risk was taken from a
meta-analysis for male-to-female transmission in de-
veloping countries,13 but our per-act URAI summary
estimate represents industrialized countries only be-
cause no relevant studies from developing countries
were identified; we assume that infectiousness varies
with viral load similarly for AI and VI and that coital
frequency remains constant over time; and again
we stress the need for caution in utilizing our
quantitative pooled estimates). Nevertheless, it
serves to vividly illustrate the large excess in HIV
risk that individuals may experience over time if
they occasionally engage in UAI with an infected
partner. Thus, prevention messages must emphasize
the high risk associated with AI and that control
measures such as condoms must be used for both
VI and AI.
Drawing conclusions on the use of HAART for HIV
prevention is beyond the scope of this article.
However, the contrasting quantitative results obtained
regarding the impact of HAART on per-partner trans-
mission risk using the two functions (Figure 3b–e)
highlight that caution is required when relying on
viral load data to predict the potential impact of
HAART on transmission and the importance of clearly
describing the model assumptions. Different viral load
functions produce different predictions (Figure 3).
Figure 3d–e demonstrates the sensitivity of results to
frequency of viral rebound and to the infectiousness
associated with these rebounds. Further work in this
area is necessary given the increasing interest in
HAART use as a prevention tool.66,67 Modelling
cannot be used as a substitute for empirical evidence,
and data are starting to become available.68
In terms of product development, oral pre-exposure
prophylaxis may be more appropriate for use among
populations where there is a high frequency of AI if
adherence to condom use or rectal microbicide use is
poor, or if microbicide efficacy is lower for AI than VI.
All microbicide trials potentially suffer from bias from
AI.69–71 There must be greater understanding of the
Table 2 Continued
Study Population Age (years) Sample
size
AI reported
(%)
Exposure
period
sexually active,
HIV-negative women
18–24, 63%
525)
Subramanian et al.,
200886
India, survey of clients
of FSW
Median 30,
18–60
4821 13.3 with
FSW
Ever
6.2 with
main regular
female
partner
Ever
8.3 with
male or
transgender
Past 6 months
Munro et al., 200887 India, community-based
survey
Mean 30,
15–49
4653 2.6g,h men Ever
0.3h women
Kalichman et al., 200988 South Africa, urban
township community-
based and urban STI
clinic surveys
Mean 31,
median 30,
minimum 18
(men and
women
combined)
2471 14.6 men Past 3 months
1646 10.4 women
FSW, female sex worker; NATSAL, National Survey of Sexual Attitudes and Lifestyles; NR, not recorded; RCT, randomized
controlled trial; STD, sexually transmitted disease.
aResults taken from review by Halperin.6
bLance M. Pollack, personal communication, September 1999 to D. Halperin.6
cTotal completing NATSAL 2000 questionnaire, including non-heterosexuals (percentage reporting AI is for heterosexual practices
only).
dAuthors report that results must be interpreted with caution as some younger pupils may have had difficulty in understanding
some of the more sensitive questions (questionnaire was self-administered), ‘in particular questions on oro-genital and anal sex’.
eNot specified in the publication.
fUAI only.
gA further 0.6% of men reported ever having had AI with another man.
hSeventeen (0.8%) of men and 68 (2.3%) of women reported not knowing if they had ever experienced AI. None of these men was
HIV positive, but among women, ‘not knowing’ was significantly associated with HIV infection, compared with the group of
women reporting no AI experience.
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role that AI plays in heterosexual as well as MSM sex
lives, particularly in regions with high HIV incidence,
so that we can design and implement measures to
minimize the role that it plays in HIV transmission.
Supplementary data
Supplementary data are available at IJE online.
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KEY MESSAGES
 UAI is a high-risk practice for HIV transmission (higher risk than VI or oro-genital intercourse),
probably with substantial variation in infectiousness and susceptibility to infection between individ-
uals, and in infectiousness over the duration of infection. The significant heterogeneity between
infectiousness estimates means that pooled AI HIV transmission probabilities should be used with
caution.
 Most studies did not collect the necessary sexual activity information required to gain a better
understanding of the relationship between per-act and per-partner risk. Variation across study esti-
mates may also partly be explained by differences in distributions of risk factors in sampled popu-
lations, study designs and various (time-varying) characteristics of the type of sexual behaviour,
characteristics of the infected partner and those of the uninfected partner.
 We found no evidence of a difference in per-act AI infectivity between heterosexual and MSM
couples.
 Model estimates of the impact of HAART in reducing HIV transmission and the mitigating effect of
AI can vary substantially, depending on the assumptions made. Empirical evidence is, therefore,
urgently needed in order to inform model estimates, which remain highly uncertain. Nevertheless,
our analysis illustrates the large excess in HIV risk that individuals may experience over time if they
occasionally engage in UAI with an infected partner. Prevention messages must emphasize the high
risk associated with AI and that control measures such as condoms must be used for both VI and AI.
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